Abstract: Hypertension is a common and growing medical problem that leads to enormous cardiovascular and kidney disease worldwide. While many drugs exist to treat hypertension, there is large individual variation in how a given individual may respond to different agents, which contributes to dismal rates of hypertension control. While demographic factors predict which drugs may work better in certain individuals, a great degree of this variation has a genetic basis. In recent years, genome wide association studies have begun to identify specific gene variants that predict drug response to particular agents. This review identifies the major genetic variants influencing antihypertensive response that have emerged from this growing body of work. For novel genetic variants without a previously known biologic basis in blood pressure, it is crucial to validate initial findings in subsequent studies. This information may eventually lead to a more personalized approach to hypertension management that will improve blood pressure control and patient outcomes. The integration of this large amount of data and its real world application will be highly challenging, but strategies to accomplish this are discussed.
Introduction
Hypertension (HTN) is responsible for significant morbidity and mortality across the United States, and indeed, worldwide. As the prevalence of obesity increases, the disease burden of hypertension will only increase [1] . The underlying pathophysiology of hypertension is complex and varies significantly between patients, which makes HTN challenging to treat successfully. There are multiple choices of drugs and drug classes to treat hypertension, and yet the rate of successful blood pressure control is disappointing, typically less than 50%, due in part to great variability between patients as to which drugs are effective. Choices of what antihypertensive class to choose can be guided partially by demographic factors, with diuretics and calcium channel blockers generally more effective in African Americans and the elderly, and beta blockers and drugs targeting the reninangiotensin system (RAS) more effective in Caucasian and younger patients [2] . Nevertheless agents are often selected in a trial and error fashion. The hit-or-miss nature of this approach is inherently inefficient and contributes to greater medical costs, delayed BP goal attainment, poorer BP management success rates, and continued high cardiovascular mortality. Predictive models or genetic information which could help identify those agents that would be most effective in a given patient would be of immense clinical value, improve BP control, and would undoubtedly reduce the consequences of hypertension and save medical costs.
Increasingly the field of pharmacogenomics has been used in areas such as cardiology and oncology to inform clinicians which drugs may have greater or lesser effectiveness as well as potentially greater risk profiles of adverse effects. The pathogenesis of elevated BP and HTN is a complex interplay of environmental and multiple genetic factors which may differ greatly between context. In contrast, a genome wide association study (GWAS) pharmacogenomic approach will identify completely novel SNPs which correlate with a greater or lesser response to specific BP agents.
After the necessary statistical correction for the very large number of multiple comparisons of hundreds of thousands of SNPs tested in each patient using current gene arrays, no SNPs have emerged with an incontestable association with BP response to any antihypertensive agent (p < 10 -8 ).
This is not surprising given the modest number of patients that can be studied in randomized trials, in contrast to the thousands of subjects analyzed in GWAS for incident HTN or other common diseases. However, multiple suggestive SNPs with p values in the 1 x 10 -5 to 1 x10 -6 range have been identified in various studies. Regardless of the strength of the genetic associations, validation populations are needed to confirm candidate SNPs that have been identified. Such an unbiased approach using a GWAS of BP response to specific antihypertensive agents has successfully identified and validated clinically relevant variants that could not have been predicted based on our current understanding of the physiology of BP regulation [11] [12] [13] . In addition to cross-validation studies, as the cost of DNA sequencing technology has fallen significantly, multiple single studies have been performed describing associations of various SNPs, but either remain unvalidated, or subsequent validation attempts have failed to confirm an effect. This review will focus on gene variants in which the evidence for a significant effect on the response to antihypertensive agents is the strongest, which emerge from high quality, well powered studies with subsequent validation in separate cohorts. A summary of important hypertension cohorts used in these pharmacogenomics analyses is given in Table 1 . which was not observed in carriers of the T allele [11] . While the pathophysiology behind this mechanism has not been uncovered yet, the independent validation and changes in YEATS4 expression level strengthen these findings; thus unexpected GWAS findings may eventually lead to a greater understanding in pathophysiology.
A separate unbiased analysis of a combined Caucasian cohort from the GERA1 and PEAR1 studies identified suggestive (P < 1 x 10 -5 ) associations between BP response to thiazides in several SNPs, and then tested these candidates for replication in a larger cohort from the GENRES (GENes and did not obtain p values < 10 -8 , they do have biologic rationale as an aldosterone sensitive regulator of ENaC (TET2), a prior association with vascular disease and HTN (CSMD1), an association with HTN and renin levels (GNB3), or a prominent role in vascular biology (VASP).
Studies showing variation at rs10995, downstream of VASP, were also interesting in that they not only predicted better blood pressure response in two independent cohorts, but also associated with the baseline level of VASP mRNA [29] . Thus the number of genes that may influence diuretic response is continuing to grow. As each genetic variant may have a relatively small influence, the challenge is to accurately integrate this information to get a more global idea of how an individual patient may respond to a certain antihypertensive drug class. An illustration of this is the combination of multiple data sets in a GWAS of HCTZ response in a combined cohort of over 1700 patients from the GENRES, GERA1, HCTZ-Milan, PHSS (Pharmacogenomics of Hydrochlorothiazide Sardinian Study), NORDIL, and PEAR1 studies. This meta-analysis did not find any Bonferroni-corrected variants of significance, but did find two suggestive (P < 10 -5 ) SNPs which correlated with response to HCTZ, and which were validated the African American group from the same studies [31] . rs177848 and rs177852 (in Caucasians and African Americans respectively) are located near FOXA1, which encodes a transcription factor, Forkhead Box A1, expressed in the collecting duct of the kidney, where it could play a role in water and solute handling [32] . Also identified in this analysis were rs11750990 and rs1049911 near GJA1, which encodes connexin 43, which functions in electrochemical coupling in myocardium and vascular smooth muscle. Lastly, a parallel survey of HTN candidate genes from this meta-analysis also implicated a series of SNPs near HSD3B1, whose gene product has a role in aldosterone synthesis [31] .
Inhibitors of the renin-angiotensin system
The renin angiotensin system (RAS) plays a key role in BP regulation and the pathophysiology of HTN, and understandably this well-defined pathway has attracted early and ongoing attention in The biological effect of this mutation on BP regulation has not been explored, but is interesting given the fact that ARBs have the clear effects on glomerular hemodynamics. Overall however, given the considerable knowledge about the physiology of the RAS, it is surprising that so few genes have been found to be relevant for predicting BP response to ACEIs and ARBs.
Beta blockers
Data supporting the influence of several genetic variants on the response to beta blockers is intriguing. The gene ADRB1 codes for the β1 receptor, and two SNPs within this gene were originally identified in population studies as a risk factor for HTN [50] . The A allele at rs1801252
leads to a Ser49 variant, which leads to increased receptor internalization, while the C allele at rs18011253 results in the Arg389Gly variant, which causes less downstream signaling to adenylyl cyclase. Multiple studies have shown that the Arg389 and/or the Ser49Arg389 haplotype are Another gene important in β1 receptor function is G protein-coupled receptor kinase 4 (GRK4), a kinase which restores β1 receptor activity after dephosphorylation by regulatory G kinases.
Polymorphisms in GRK4 (rs2960306 and rs1024323) were initially found in an analysis of the AASK study (African American Study of Kidney Disease and Hypertension) to influence the time to BP control with metoprolol, although this was seen only in men [61] . The AASK trial enrolled African
Americans with hypertensive nephrosclerosis and thus by design focused on individuals with poor kidney function. This finding was clarified in a mixed race populations in the PEAR1 study, which had excluded individuals with abnormal kidney function [62] . Here the number of copies of the 65Leu142Val haplotype of rs2960306/rs1024323 correlated with decreased DBP responsiveness to atenolol (-9.1, -6.8, and -5.3 mm Hg in those with 0, 1, and 2 copies), an effect present in either gender.
Furthermore the 486Val variant (rs1801058) was found in the INVEST trial to correlate with worse Beyond the above genes which have a known biologic mechanism in adrenergic signaling, several other genes have emerged from unbiased analyses. One key study identified two SNPs which influenced response to beta blocker monotherapy in a combined African American cohort from the PEAR1 and PEAR2 studies. These SNPs were successfully validated in a second group of patients from PEAR1 in whom atenolol was added after HCTZ. rs201279313, a deletion of TTA in an intron of SLC25A31, was associated with a greater DBP response (p=2.5 x 10 -8 in combined metaanalysis) [12] . This gene codes for a mitochondrial membrane ATP/ADP transporter. This study also found that the deletion variant of rs11313667 correlated with better SBP response to beta blockers (p=7.2 x 10 -8 ). rs11313667 is intronic to the gene LRRC15, which encodes leucine rich repeat containing 15, a glycoprotein normally associated with placenta and cancers. Although the biologic basis of this effect is unknown, it could also be mediated via nearby genes, such as GP5 (platelet glycoprotein V), which mediates the adhesion platelets to the endothelium and has been reported to be elevated in HTN [63] .
Another example of the use of an unbiased GWAS to discover a gene influencing BP response is the gene PTPRD. Analysis of the Caucasian cohort of patients from the PEAR1 study found that SNP rs12346562, located upstream of PTPRD, correlates with improved BP response to beta blocker (p=3.2 x 10 -6 ), with an opposite direction of effect seen in HCTZ [64] . This finding was confirmed in the Finnish population of the GENRES study; rs12346562 was also found to be linked with resistant receptor delta, which has been found to have roles in neuron growth and guidance as well as malignant glioma, although through its involvement in the STAT3 pathway could possibly play a role in intrarenal RAS signaling [65] . Further support for this is given by the identification of a SNP rs10739150 downstream of PTPRD that correlates with BP responsiveness in the African American group from this study (p=8.3 x 10 -6 ).
The Caucasian cohort from the PEAR1 study was analyzed to determine if a selected set of 37
SNPs previously associated with baseline HTN predicted BP response to atenolol or HCTZ. While none of these SNPs achieved genome wide significance, six did reach nominal significance. Of these, rs1458038, near the FGF5 gene (Fibroblast Growth Factor 5), had the most powerful effect. The T allele of rs1458038 was significantly associated with better BP response to atenolol, while being associated with decreased response to HCTZ [66] . The relationship of this SNP to HTN at baseline in prior studies, the opposite directions of effect in different drug classes, and the strong linear relationship between the number of T alleles and both SBP and DBP response all support a likely association. This analysis additionally combined several others of these significant SNPs to calculate genetic scores accounting for 8.5% and 4.3% of the variation in SBP response to atenolol and HCTZ respectively. Of note, none of these variants had significant associations in the African American population within PEAR1. This level of prediction for BP response is considerably stronger than what has been observed for a risk score explaining the degree of untreated BP at baseline, which was estimated to be approximately 2.2% using the combined effect of 116 independent loci [67] . [73] . A second SNP in this gene, rs11014166, was associated with outcome differences within the Hispanic subpopulation of this study. While BP response was not directly tracked as an outcome measure in these studies, the differences in outcome seen only in the verapamil treated group suggest a genetic basis for differential sensitivity to calcium channel blockers with these variants.
While the above findings were all directed at biologically based candidate genes, one study of a Caucasian cohort from the INVEST study used a GWAS of nonsynonymous SNPs to develop a risk score to identify differential mortality benefits with a CCB versus beta blocker treatment [74] . The derived risk score was based on the additive effect of three novel variants: rs16982743, rs893184, and rs4525, respectively located within SIGLEC12, A1BG, and F5. This score ranged from 0-3; a score of 0-1 was associated with improved outcomes in those treated with a CCB (OR 0.60, 95% CI 0.42-0.86), while a score of 2-3 was significantly associated with worse cardiovascular outcomes with a CCB 
Pharmacokinetic influences
In addition to candidates based on mechanism of action, the response to several BP drugs is known to be influenced by genes influencing their metabolism. Losartan is a prodrug metabolized by cytochrome P450 enzymes CYP2C9, and to a lesser degree CYP3A4, to its active form [76] .
Variants in CYP2C9 have been found which are associated with markedly slow conversion of losartan to its active metabolite, with significantly reduced effects on blood pressure and proteinuria [41, 45, 77] . Metoprolol is primarily metabolized by CYP2D6, which has multiple variant alleles, some of which are nonfunctional or hypofunctional [78, 79] . Individuals carrying hypofunctional alleles have been found to have higher metoprolol blood levels, as well as differences in diastolic blood pressure (DBP), heart rate, and QT interval [80, 81] . Additionally increased copy number of CYP2D6 can cause some individuals to be rapid metabolizers of metoprolol [82] . Based on this, the Dutch pharmacogenomics working Group (DPWG) has formally recommended CYP2D6 testing with metoprolol [83] . We have an incomplete knowledge of genetic influences on the pharmacokinetics of most antihypertensive drugs, but variations in drug levels may not always translate into meaningful differences in drug effect. An example is carvedilol, which is also metabolized by CYP2D6, with resultant differences in carvedilol drug levels, although differences in BP or other clinical effects have not been consistently observed [60, 84] . Amlodipine and verapamil are known to be metabolized by CYP3A4 and CYP3A5 [85, 86] . Several gene variants in the former were associated with better BP control with amlodipine in women in the AASK trial [85] . Lastly,
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hydralazine metabolism is affected by variants in its phase II metabolizing enzyme Nacetyltransferase-2. Individuals carrying NAT2*5, *6, and *7 alleles, present in up to 90% of North Africans and 50% of Caucasians, are more likely to have high drug levels and greater blood pressure response [87, 88] .
Adverse effects
In addition to immediate and longer term effectiveness of antihypertensives, some work has been directed at uncovering genetic predictors of known adverse effects from these drugs. Single studies have implicated potential variants that predict HCTZ-induced hypokalemia, hyperuricemia, or dyslipidemia with HCTZ or atenolol [89] [90] [91] . These studies have not yet been validated, but one study examining a panel of 33 candidate genetic variants previously associated with fasting glucose in the general population found that rs340874, located upstream of PROX1, was associated with atenolol induced hyperglycemia with a Caucasian cohort of the PEAR1 study [92] . PROX1 encodes prospero homeobox 1, which has a role in embryologic development of liver and pancreas, and may be involved in liver gluconeogenesis [93] . Additionally, an association between thiazide induced hyperglycemia and variants in renal potassium channel KCNJ1 was also suggested in an analysis of several candidate genes [94] . Subsequently, an analysis the African American cohort of the PEAR1 study found that variation at rs17137967, located within an intron of KCNJ1, was associated with thiazide induced new onset diabetes, subsequently confirmed in a multiracial group from the INVEST study [95] . Other work has explored predictors of the common problem of ACE-I induced cough, based not on a GWAS approach but by focus on genes with possible biologic rationale. An earlier finding that differences in the promotor region of bradykinin B2 receptor (BDKRB2) has not [99] [100] [101] . Identification of patients at risk of adverse effects from antihypertensive drugs has not been nearly as well studied as genetic influences on drug efficacy, but could have a major impact on patient care and health care expenses.
Where do we go from here?
The above studies show the large and growing amount of knowledge we have gained about pharmacogenomic data exist in the significant proportion of hypertensive patients with chronic kidney disease. As well, patients with resistant HTN (requiring more than three drugs for control)
is another important group that may behave differently that what the above trials suggest, although some recent work is beginning to address this [104] [105] [106] . The identification of some novel genes also advances our understanding of human biology. Furthermore, another limitation to the GWAS approach is that using genetic arrays of known SNPs by definition excludes rare variants with allele frequencies < 0.05, thus inevitably the influence of rare but potentially powerful variants will not been detected. This may change as the cost of whole exon or whole genome sequencing becomes more feasible in the near future. Perhaps the greatest challenge is simply bringing together the vast amount of genetic information these many studies have now generated. Increasingly, work has combined cohorts from multiple studies to increase overall statistical power. While inevitably there are concerns about heterogeneity between different studies, this is clearly a step forward. The ICAPS (International Consortium for Antihypertensives Pharmacogenomics Studies) consortium, founded in 2012, has been a key force in advancing this work. ICAPS now has 29 clinical trials with 345,000 participants' data available for analysis. These better powered analyses allows calculation of risk scores using weighted combinations of multiple allelic variants which can better predict the response to different blood pressure agents [74, 107] . Inclusion of other demographic or clinical data in such a score could further enhance accuracy of these models. One clear obstacle is the cost of genetic testing. While advancing technology has made genetic testing vastly less expensive than even five years ago, obtaining pharmacogenetics information on individual patients will still ultimately require insurance coverage for the vast majority of cases.
Another impediment is that when genetic information becomes routinely available, individual physicians may vary widely in their comfort level interpreting and actually using pharmacogenomic data to make treatment decisions for their patients. Many current physicians had their medical training in an era before the sequencing of the human genome was achievable, and medical curricula pharmacogenomic information. Patients with difficult to control HTN are a subset in whom this approach may be the most natural, as well as being a group who may have the most to gain [104] .
Despite these difficulties, a streamlined pharmacogenomic approach to get hypertensive patients on the most effective, efficient, and well tolerated drug regimen would have great benefits.
This would result in fewer patient visits to readjust BP medications, fewer drugs per patient, and likely better compliance with their medical regimen. Better BP control would doubtless lead to fewer cardiovascular and renal complications and thus great improvement in quality of life and longevity [108] [109] [110] . Given the vast numbers of patients with HTN, this would as well result in enormous cost savings, with one recent economic analysis estimating national cost savings of $42 billion/year [111] . While this expectation appears straightforward, demonstration of such improved outcomes in clinical trials would be a powerful stimulus to bring pharmacogenomics into clinical use in patients with HTN.
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